Gibson Christopher's most recent trade in Recursion Pharmaceuticals Inc - Ordinary Shares - Class A was a trade of 40,390 Class A Common Stock done at an average price of $4.1 . Disclosure was reported to the exchange on Nov. 17, 2025.
| Stock | Client Name | Client Category | Action | Reported to Exchange | Quantity | Post Transaction Holding | Traded % | Avg. Price | Value | Security Type |
|---|---|---|---|---|---|---|---|---|---|---|
| Recursion Pharmaceuticals Inc | Christopher Gibson | Director, Chief Executive Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 4.14 per share. | 17 Nov 2025 | 40,390 | 913,839 | - | 4.1 | 167,215 | Class A Common Stock |
| Recursion Pharmaceuticals Inc | Christopher Gibson | Director, Chief Executive Officer | 17 Nov 2025 | 40,000 | 4,823,334 | - | - | Class B Common Stock | ||
| Recursion Pharmaceuticals Inc | Christopher Gibson | Director, Chief Executive Officer | Sale of securities on an exchange or to another person at price $ 4.16 per share. | 17 Nov 2025 | 40,000 | 913,839 | - | 4.2 | 166,400 | Class A Common Stock |
| Recursion Pharmaceuticals Inc | Christopher Gibson | Director, Chief Executive Officer | 17 Nov 2025 | 40,000 | 953,839 | - | 0 | Class A Common Stock | ||
| Recursion Pharmaceuticals Inc | Christopher Gibson | Director, Chief Executive Officer | 04 Nov 2025 | 60,000 | 4,863,334 | - | - | Class B Common Stock | ||
| Recursion Pharmaceuticals Inc | Christopher Gibson | Director, Chief Executive Officer | 04 Nov 2025 | 60,000 | 1,014,229 | - | 0 | Class A Common Stock | ||
| Recursion Pharmaceuticals Inc | Christopher Gibson | Director, Chief Executive Officer | Sale of securities on an exchange or to another person at price $ 5.21 per share. | 04 Nov 2025 | 40,000 | 974,229 | - | 5.2 | 208,400 | Class A Common Stock |
| Recursion Pharmaceuticals Inc | Christopher Gibson | Director, Chief Executive Officer | Gift of securities by or to the insider at price $ 0.00 per share. | 04 Nov 2025 | 20,000 | 954,229 | - | 0 | Class A Common Stock | |
| Recursion Pharmaceuticals Inc | Christopher Gibson | Director, Chief Executive Officer | 23 Oct 2025 | 100,000 | 4,923,334 | - | - | Class B Common Stock | ||
| Recursion Pharmaceuticals Inc | Christopher Gibson | Director, Chief Executive Officer | Sale of securities on an exchange or to another person at price $ 5.70 per share. | 23 Oct 2025 | 100,000 | 954,229 | - | 5.7 | 570,000 | Class A Common Stock |
| Recursion Pharmaceuticals Inc | Christopher Gibson | Director, Chief Executive Officer | 23 Oct 2025 | 100,000 | 1,054,229 | - | 0 | Class A Common Stock | ||
| Recursion Pharmaceuticals Inc | Christopher Gibson | Director, Chief Executive Officer | 10 Oct 2025 | 120,000 | 1,074,229 | - | 0 | Class A Common Stock | ||
| Recursion Pharmaceuticals Inc | Christopher Gibson | Director, Chief Executive Officer | 10 Oct 2025 | 120,000 | 5,133,034 | - | - | Class B Common Stock | ||
| Recursion Pharmaceuticals Inc | Christopher Gibson | Director, Chief Executive Officer | Sale of securities on an exchange or to another person at price $ 6.04 per share. | 10 Oct 2025 | 100,000 | 974,229 | - | 6.0 | 604,000 | Class A Common Stock |
| Recursion Pharmaceuticals Inc | Christopher Gibson | Director, Chief Executive Officer | Gift of securities by or to the insider at price $ 0.00 per share. | 10 Oct 2025 | 20,000 | 954,229 | - | 0 | Class A Common Stock | |
| Recursion Pharmaceuticals Inc | Christopher Gibson | Director, Chief Executive Officer | 25 Sep 2025 | 100,000 | 1,054,229 | - | 0 | Class A Common Stock | ||
| Recursion Pharmaceuticals Inc | Christopher Gibson | Director, Chief Executive Officer | Sale of securities on an exchange or to another person at price $ 4.76 per share. | 25 Sep 2025 | 100,000 | 954,229 | - | 4.8 | 476,000 | Class A Common Stock |
| Recursion Pharmaceuticals Inc | Christopher Gibson | Director, Chief Executive Officer | 10 Sep 2025 | 120,000 | 1,074,229 | - | 0 | Class A Common Stock | ||
| Recursion Pharmaceuticals Inc | Christopher Gibson | Director, Chief Executive Officer | 10 Sep 2025 | 120,000 | 5,253,034 | - | - | Class B Common Stock | ||
| Recursion Pharmaceuticals Inc | Christopher Gibson | Director, Chief Executive Officer | Sale of securities on an exchange or to another person at price $ 4.71 per share. | 10 Sep 2025 | 100,000 | 974,229 | - | 4.7 | 471,000 | Class A Common Stock |
| Recursion Pharmaceuticals Inc | Christopher Gibson | Director, Chief Executive Officer | Gift of securities by or to the insider at price $ 0.00 per share. | 10 Sep 2025 | 20,000 | 954,229 | - | 0 | Class A Common Stock | |
| Recursion Pharmaceuticals Inc | Christopher Gibson | Director, Chief Executive Officer | 26 Aug 2025 | 100,000 | 5,373,034 | - | - | Class B Common Stock | ||
| Recursion Pharmaceuticals Inc | Christopher Gibson | Director, Chief Executive Officer | Sale of securities on an exchange or to another person at price $ 4.84 per share. | 26 Aug 2025 | 100,000 | 954,229 | - | 4.8 | 484,000 | Class A Common Stock |
| Recursion Pharmaceuticals Inc | Christopher Gibson | Director, Chief Executive Officer | 26 Aug 2025 | 100,000 | 1,054,229 | - | 0 | Class A Common Stock | ||
| Recursion Pharmaceuticals Inc | Christopher Gibson | Director, Chief Executive Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 5.64 per share. | 15 Aug 2025 | 40,390 | 954,229 | - | 5.6 | 227,800 | Class A Common Stock |
| Recursion Pharmaceuticals Inc | Christopher Gibson | Director, Chief Executive Officer | Sale of securities on an exchange or to another person at price $ 5.28 per share. | 11 Aug 2025 | 500,300 | 1,004,619 | - | 5.3 | 2,641,584 | Class A Common Stock |
| Recursion Pharmaceuticals Inc | Christopher Gibson | Director, Chief Executive Officer | 11 Aug 2025 | 423,666 | 1,504,919 | - | 0 | Class A Common Stock | ||
| Recursion Pharmaceuticals Inc | Christopher Gibson | Director, Chief Executive Officer | 11 Aug 2025 | 423,666 | 5,473,034 | - | - | Class B Common Stock | ||
| Recursion Pharmaceuticals Inc | Christopher Gibson | Director, Chief Executive Officer | 11 Aug 2025 | 100,000 | 386,000 | - | - | Class B Common Stock | ||
| Recursion Pharmaceuticals Inc | Christopher Gibson | Director, Chief Executive Officer | Sale of securities on an exchange or to another person at price $ 5.28 per share. | 11 Aug 2025 | 100,000 | 0 | - | 5.3 | 528,000 | Class A Common Stock |
| Recursion Pharmaceuticals Inc | Christopher Gibson | Director, Chief Executive Officer | 11 Aug 2025 | 100,000 | 100,000 | - | 0 | Class A Common Stock | ||
| Recursion Pharmaceuticals Inc | Christopher Gibson | Director, Chief Executive Officer | Sale of securities on an exchange or to another person at price $ 5.28 per share. | 11 Aug 2025 | 17,875 | 0 | - | 5.3 | 94,380 | Class A Common Stock |
| Recursion Pharmaceuticals Inc | Christopher Gibson | Director, Chief Executive Officer | 11 Aug 2025 | 17,875 | 17,875 | - | 0 | Class A Common Stock | ||
| Recursion Pharmaceuticals Inc | Christopher Gibson | Director, Chief Executive Officer | 11 Aug 2025 | 17,875 | 50,000 | - | - | Class B Common Stock | ||
| Recursion Pharmaceuticals Inc | Christopher Gibson | Director, Chief Executive Officer | Gift of securities by or to the insider at price $ 0.00 per share. | 11 Aug 2025 | 10,000 | 994,619 | - | 0 | Class A Common Stock | |
| Recursion Pharmaceuticals Inc | Christopher Gibson | Director, Chief Executive Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 4.25 per share. | 15 May 2025 | 36,197 | 1,081,253 | - | 4.2 | 153,837 | Class A Common Stock |
| Recursion Pharmaceuticals Inc | Christopher Gibson | Director, Chief Executive Officer | Sale of securities on an exchange or to another person at price $ 6.04 per share. | 27 Mar 2025 | 138,574 | 1,117,450 | - | 6.0 | 836,987 | Class A Common Stock |
| Recursion Pharmaceuticals Inc | Christopher Gibson | Director, Chief Executive Officer | 05 Mar 2025 | 20,000 | 1,276,024 | - | 0 | Class A Common Stock | ||
| Recursion Pharmaceuticals Inc | Christopher Gibson | Director, Chief Executive Officer | 05 Mar 2025 | 20,000 | 5,896,700 | - | - | Class B Common Stock | ||
| Recursion Pharmaceuticals Inc | Christopher Gibson | Director, Chief Executive Officer | 05 Mar 2025 | 20,000 | 5,916,700 | - | - | Class B Common Stock | ||
| Recursion Pharmaceuticals Inc | Christopher Gibson | Director, Chief Executive Officer | Sale of securities on an exchange or to another person at price $ 6.37 per share. | 05 Mar 2025 | 20,000 | 1,256,024 | - | 6.4 | 127,400 | Class A Common Stock |
| Recursion Pharmaceuticals Inc | Christopher Gibson | Director, Chief Executive Officer | 05 Mar 2025 | 20,000 | 1,276,024 | - | 0 | Class A Common Stock | ||
| Recursion Pharmaceuticals Inc | Christopher Gibson | Director, Chief Executive Officer | Sale of securities on an exchange or to another person at price $ 6.58 per share. | 05 Mar 2025 | 20,000 | 1,256,024 | - | 6.6 | 131,600 | Class A Common Stock |
| Recursion Pharmaceuticals Inc | Christopher Gibson | Director, Chief Executive Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 10.64 per share. | 18 Feb 2025 | 17,132 | 1,256,024 | - | 10.6 | 182,284 | Class A Common Stock |
| Recursion Pharmaceuticals Inc | Christopher Gibson | Director, Chief Executive Officer | 05 Feb 2025 | 20,000 | 1,293,156 | - | 0 | Class A Common Stock | ||
| Recursion Pharmaceuticals Inc | Christopher Gibson | Director, Chief Executive Officer | 05 Feb 2025 | 20,000 | 5,936,700 | - | - | Class B Common Stock | ||
| Recursion Pharmaceuticals Inc | Christopher Gibson | Director, Chief Executive Officer | 05 Feb 2025 | 20,000 | 5,956,700 | - | - | Class B Common Stock | ||
| Recursion Pharmaceuticals Inc | Christopher Gibson | Director, Chief Executive Officer | Sale of securities on an exchange or to another person at price $ 8.12 per share. | 05 Feb 2025 | 20,000 | 1,273,156 | - | 8.1 | 162,400 | Class A Common Stock |
| Recursion Pharmaceuticals Inc | Christopher Gibson | Director, Chief Executive Officer | 05 Feb 2025 | 20,000 | 1,293,156 | - | 0 | Class A Common Stock | ||
| Recursion Pharmaceuticals Inc | Christopher Gibson | Director, Chief Executive Officer | Sale of securities on an exchange or to another person at price $ 7.68 per share. | 05 Feb 2025 | 20,000 | 1,273,156 | - | 7.7 | 153,600 | Class A Common Stock |
| Recursion Pharmaceuticals Inc | Christopher Gibson | Director, Chief Executive Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 03 Feb 2025 | 1,050,567 | 1,050,567 | - | - | Stock Option (Right to Buy) | |
| Recursion Pharmaceuticals Inc | Christopher Gibson | Director, Chief Executive Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 03 Feb 2025 | 525,283 | 1,261,916 | - | 0 | Class A Common Stock | |
| Recursion Pharmaceuticals Inc | Christopher Gibson | Director, Chief Executive Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 03 Feb 2025 | 16,809 | 1,278,725 | - | 0 | Class A Common Stock | |
| Recursion Pharmaceuticals Inc | Christopher Gibson | Director, Chief Executive Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 7.25 per share. | 03 Feb 2025 | 5,569 | 1,273,156 | - | 7.2 | 40,375 | Class A Common Stock |
| Recursion Pharmaceuticals Inc | Christopher Gibson | Director, Chief Executive Officer | 08 Jan 2025 | 20,000 | 756,633 | - | 0 | Class A Common Stock | ||
| Recursion Pharmaceuticals Inc | Christopher Gibson | Director, Chief Executive Officer | Sale of securities on an exchange or to another person at price $ 7.31 per share. | 08 Jan 2025 | 20,000 | 736,633 | - | 7.3 | 146,200 | Class A Common Stock |
| Recursion Pharmaceuticals Inc | Christopher Gibson | Director, Chief Executive Officer | 08 Jan 2025 | 20,000 | 756,633 | - | 0 | Class A Common Stock | ||
| Recursion Pharmaceuticals Inc | Christopher Gibson | Director, Chief Executive Officer | Sale of securities on an exchange or to another person at price $ 7.05 per share. | 08 Jan 2025 | 20,000 | 736,633 | - | 7.1 | 141,000 | Class A Common Stock |
| Recursion Pharmaceuticals Inc | Christopher Gibson | Director, Chief Executive Officer | 08 Jan 2025 | 20,000 | 5,996,700 | - | - | Class B Common Stock | ||
| Recursion Pharmaceuticals Inc | Christopher Gibson | Director, Chief Executive Officer | 08 Jan 2025 | 20,000 | 5,976,700 | - | - | Class B Common Stock | ||
| Recursion Pharmaceuticals Inc | Christopher Gibson | Director, Chief Executive Officer | 04 Dec 2024 | 20,000 | 756,633 | - | 0 | Class A Common Stock | ||
| Recursion Pharmaceuticals Inc | Christopher Gibson | Director, Chief Executive Officer | 04 Dec 2024 | 20,000 | 6,016,700 | - | - | Class B Common Stock | ||
| Recursion Pharmaceuticals Inc | Christopher Gibson | Director, Chief Executive Officer | 04 Dec 2024 | 20,000 | 6,036,700 | - | - | Class B Common Stock | ||
| Recursion Pharmaceuticals Inc | Christopher Gibson | Director, Chief Executive Officer | Sale of securities on an exchange or to another person at price $ 7.12 per share. | 04 Dec 2024 | 20,000 | 736,633 | - | 7.1 | 142,400 | Class A Common Stock |
| Recursion Pharmaceuticals Inc | Christopher Gibson | Director, Chief Executive Officer | 04 Dec 2024 | 20,000 | 756,633 | - | 0 | Class A Common Stock | ||
| Recursion Pharmaceuticals Inc | Christopher Gibson | Director, Chief Executive Officer | Sale of securities on an exchange or to another person at price $ 7.16 per share. | 04 Dec 2024 | 20,000 | 736,633 | - | 7.2 | 143,200 | Class A Common Stock |
| Recursion Pharmaceuticals Inc | Christopher Gibson | Director, Chief Executive Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 6.17 per share. | 15 Nov 2024 | 26,023 | 736,633 | - | 6.2 | 160,692 | Class A Common Stock |
| Recursion Pharmaceuticals Inc | Christopher Gibson | Director, Chief Executive Officer | 13 Nov 2024 | 20,000 | 782,656 | - | 0 | Class A Common Stock | ||
| Recursion Pharmaceuticals Inc | Christopher Gibson | Director, Chief Executive Officer | 13 Nov 2024 | 20,000 | 6,056,700 | - | - | Class B Common Stock | ||
| Recursion Pharmaceuticals Inc | Christopher Gibson | Director, Chief Executive Officer | 13 Nov 2024 | 20,000 | 6,076,700 | - | - | Class B Common Stock | ||
| Recursion Pharmaceuticals Inc | Christopher Gibson | Director, Chief Executive Officer | Sale of securities on an exchange or to another person at price $ 7.35 per share. | 13 Nov 2024 | 20,000 | 762,656 | - | 7.4 | 147,000 | Class A Common Stock |
| Recursion Pharmaceuticals Inc | Christopher Gibson | Director, Chief Executive Officer | 13 Nov 2024 | 20,000 | 782,656 | - | 0 | Class A Common Stock | ||
| Recursion Pharmaceuticals Inc | Christopher Gibson | Director, Chief Executive Officer | Sale of securities on an exchange or to another person at price $ 7.74 per share. | 13 Nov 2024 | 20,000 | 762,656 | - | 7.7 | 154,800 | Class A Common Stock |
| Recursion Pharmaceuticals Inc | Christopher Gibson | Director, Chief Executive Officer | 02 Oct 2024 | 20,000 | 782,656 | - | 0 | Class A Common Stock | ||
| Recursion Pharmaceuticals Inc | Christopher Gibson | Director, Chief Executive Officer | Sale of securities on an exchange or to another person at price $ 6.08 per share. | 02 Oct 2024 | 20,000 | 762,656 | - | 6.1 | 121,600 | Class A Common Stock |
| Recursion Pharmaceuticals Inc | Christopher Gibson | Director, Chief Executive Officer | 02 Oct 2024 | 20,000 | 782,656 | - | 0 | Class A Common Stock | ||
| Recursion Pharmaceuticals Inc | Christopher Gibson | Director, Chief Executive Officer | Sale of securities on an exchange or to another person at price $ 6.16 per share. | 02 Oct 2024 | 20,000 | 762,656 | - | 6.2 | 123,200 | Class A Common Stock |
| Recursion Pharmaceuticals Inc | Christopher Gibson | Director, Chief Executive Officer | 02 Oct 2024 | 20,000 | 6,096,700 | - | - | Class B Common Stock | ||
| Recursion Pharmaceuticals Inc | Christopher Gibson | Director, Chief Executive Officer | 02 Oct 2024 | 20,000 | 6,116,700 | - | - | Class B Common Stock | ||
| Recursion Pharmaceuticals Inc | Christopher Gibson | Director, Chief Executive Officer | Sale of securities on an exchange or to another person at price $ 6.14 per share. | 04 Sep 2024 | 20,000 | 762,656 | - | 6.1 | 122,800 | Class A Common Stock |
| Recursion Pharmaceuticals Inc | Christopher Gibson | Director, Chief Executive Officer | 04 Sep 2024 | 20,000 | 782,656 | - | 0 | Class A Common Stock | ||
| Recursion Pharmaceuticals Inc | Christopher Gibson | Director, Chief Executive Officer | Sale of securities on an exchange or to another person at price $ 6.04 per share. | 04 Sep 2024 | 20,000 | 762,656 | - | 6.0 | 120,800 | Class A Common Stock |
| Recursion Pharmaceuticals Inc | Christopher Gibson | Director, Chief Executive Officer | 04 Sep 2024 | 20,000 | 782,656 | - | 0 | Class A Common Stock | ||
| Recursion Pharmaceuticals Inc | Christopher Gibson | Director, Chief Executive Officer | 04 Sep 2024 | 20,000 | 6,136,700 | - | - | Class B Common Stock | ||
| Recursion Pharmaceuticals Inc | Christopher Gibson | Director, Chief Executive Officer | 04 Sep 2024 | 20,000 | 6,156,700 | - | - | Class B Common Stock | ||
| Recursion Pharmaceuticals Inc | Christopher Gibson | Director, Chief Executive Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 2.48 per share. | 30 Aug 2024 | 5,000 | 762,656 | - | 2.5 | 12,400 | Class A Common Stock |
| Recursion Pharmaceuticals Inc | Christopher Gibson | Director, Chief Executive Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 30 Aug 2024 | 5,000 | 282,500 | - | - | Stock Option (Right to Buy) | |
| Recursion Pharmaceuticals Inc | Christopher Gibson | Director, Chief Executive Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 2.48 per share. | 29 Aug 2024 | 5,000 | 757,656 | - | 2.5 | 12,400 | Class A Common Stock |
| Recursion Pharmaceuticals Inc | Christopher Gibson | Director, Chief Executive Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 29 Aug 2024 | 5,000 | 287,500 | - | - | Stock Option (Right to Buy) | |
| Recursion Pharmaceuticals Inc | Christopher Gibson | Director, Chief Executive Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 2.48 per share. | 28 Aug 2024 | 5,000 | 752,656 | - | 2.5 | 12,400 | Class A Common Stock |
| Recursion Pharmaceuticals Inc | Christopher Gibson | Director, Chief Executive Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 28 Aug 2024 | 5,000 | 292,500 | - | - | Stock Option (Right to Buy) | |
| Recursion Pharmaceuticals Inc | Christopher Gibson | Director, Chief Executive Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 2.48 per share. | 27 Aug 2024 | 5,000 | 747,656 | - | 2.5 | 12,400 | Class A Common Stock |
| Recursion Pharmaceuticals Inc | Christopher Gibson | Director, Chief Executive Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 27 Aug 2024 | 5,000 | 297,500 | - | - | Stock Option (Right to Buy) | |
| Recursion Pharmaceuticals Inc | Christopher Gibson | Director, Chief Executive Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 26 Aug 2024 | 5,000 | 302,500 | - | - | Stock Option (Right to Buy) | |
| Recursion Pharmaceuticals Inc | Christopher Gibson | Director, Chief Executive Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 2.48 per share. | 26 Aug 2024 | 5,000 | 742,656 | - | 2.5 | 12,400 | Class A Common Stock |
| Recursion Pharmaceuticals Inc | Christopher Gibson | Director, Chief Executive Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 23 Aug 2024 | 5,000 | 307,500 | - | - | Stock Option (Right to Buy) | |
| Recursion Pharmaceuticals Inc | Christopher Gibson | Director, Chief Executive Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 2.48 per share. | 23 Aug 2024 | 5,000 | 737,656 | - | 2.5 | 12,400 | Class A Common Stock |
| Recursion Pharmaceuticals Inc | Christopher Gibson | Director, Chief Executive Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 6.69 per share. | 15 Aug 2024 | 26,082 | 732,656 | - | 6.7 | 174,489 | Class A Common Stock |
| Recursion Pharmaceuticals Inc | Christopher Gibson | Director, Chief Executive Officer | 07 Aug 2024 | 30,000 | 788,738 | - | 0 | Class A Common Stock | ||
| Recursion Pharmaceuticals Inc | Christopher Gibson | Director, Chief Executive Officer | 07 Aug 2024 | 30,000 | 6,196,700 | - | - | Class B Common Stock | ||
| Recursion Pharmaceuticals Inc | Christopher Gibson | Director, Chief Executive Officer | Sale of securities on an exchange or to another person at price $ 7.10 per share. | 07 Aug 2024 | 30,000 | 758,738 | - | 7.1 | 213,000 | Class A Common Stock |